[关键词]
[摘要]
目的:探讨血清同型半胱氨酸(Hcy)水平与2型糖尿病合并前部缺血性视神经病变(AION)的关系。
方法:选取2016-01/2019-04于河北省眼科医院就诊的2型糖尿病患者100例,依据是否并发AION分为未合并AION组(A组,53例)和合并AION组(B组,47例),另选取同期健康体检者38例为对照组(C组)。检测受检者血Hcy、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、肌酐(Cr)、糖化血红蛋白(HbA1c)等生化指标和血压、最佳矫正视力(BCVA)情况,分析2型糖尿病合并AION患者血Hcy水平与上述临床指标的相关性。
结果:B组受检者血Hcy水平(13.87±5.02μmol/L)显著高于A组(11.83±3.49μmol/L)和C组(11.06±3.62μmol/L)(均P<0.05),且B组受检者HHcy发生率(36.2%)明显高于A组(11.3%)和C组(10.5%)。校正年龄、TG、LDL-C、Cr、糖尿病病程、收缩压和舒张压后,2型糖尿病合并AION患者血Hcy水平与HbA1c水平呈正相关(r=0.517,P=0.001),与BCVA呈负相关(r=-0.353,P=0.026)。
结论:血清Hcy可能参与了2型糖尿病患者AION的发病过程,其可作为防治2型糖尿病合并AION的潜在靶点。
[Key word]
[Abstract]
AIM: To investigate the relationship between serum homocysteine(Hcy)and anterior ischemic optic neuropathy(AION)in patients with type 2 diabetes mellitus.
METHODS: One hundred patients with type 2 diabetes mellitus who treated in Hebei Eye Hospital from January 2016 to April 2019 were divided into two groups: group A(n=53)without AION, group B(n=47)with AION. Thirty-eight healthy volunteers were used as control group(group C). The serum levels of Hcy, triglyceride cholesterol(TG), low density lipoprotein cholesterol(LDL-C), creatinine(Cr), gycosylated hemoglobin(HbA1c), blood pressure, best corrected visual acuity were detected. To analyze the correlation between serum Hcy level and the clinical indicators in AION in patients with type 2 diabetes mellitus.
RESULTS: The level of Hcy in group B was significantly higher than that in group A and group C \〖(13.87±5.02)μmol/L ratio(11.83±3.49)μmol/L, and(11.06±3.62)μmol/L, all P<0.05\〗.The group B HHcy incidence(36.2%)was significantly higher than that in group A(11.3%)and group C(10.5%).The level of Hcy was positively correlated with HbA1c(r=0.517, P=0.001)and negatively correlated with BCVA(r=-0.353, P=0.026)after adjustment for age, TG, LDL-C, Cr, systolic blood pressure, diastolic blood pressure and course of diabetes mellitus.
CONCLUSION: The level of Hcy in serum may be involved in the pathogenesis of AION in type 2 diabetic patients. Hcy may be a potential target for preventing and treating AION in type 2 diabetic patients.
[中图分类号]
[基金项目]